KlaAtlas ยท Dataset details
PXD045069
Herbal medicine formula Huazhuo Tiaozhi granule ameliorates dyslipidaemia via regulating histone lactylation and miR-155-5p biogenesis
Back to datasets
1,219
Reidentified Kla sites
657
Reidentified Kla proteins
2
Raw MS files
Dataset overview
Dataset accession
Repository
PRIDE
Publication
UniProt taxonomy ID
9606
Sample category
Cell line
Tissue / cell type
Human LO2 (L02) liver cell line
Experimental condition / comparison
FFA model versus FFA model with Huazhuo Tiaozhi granule (HTG) comparison.
Experimental information
Acquisition workflow
Reporter MS2
MS platform
Orbitrap
Quantification strategy
TMT
Kla enrichment method
Pre-washed antibody-bead enrichment of modified peptides
Enrichment reagent supplier
Jingjie PTM BioLabs
Reagent catalogue information
Not specified in accessible enrichment protocol
Data access
MaxQuant parameter files
PXD045069_mqpar.xml
Raw MS file information
2 processed acquisition files.
Original raw data may be accessed
through the source repository.
Show raw MS file names (2 files)
- XA01378LPLa_FFA_Slot2-1_1_25192.d
- XA01378LPLa_HTG_Slot2-2_1_25194.d
Metadata sources
DOI: 10.1186/s13148-023-01573-y
PRIDE PXD045069
Evidence E01-E03
PRIDE PXD045069
Evidence E01-E03
Dataset notes
Sample information and limitations
Two selected acquisitions named FFA and HTG. Published Methods report TMT and Q Exactive HF-X, whereas selected RAWs are Bruker acquisitions. Reporter-channel sample key, pooling and independent preparations remain unresolved. Ordinary evidence-derived Intensity does not establish or disprove the original labeling method.
Experimental metadata notes
FFA model versus FFA model with Huazhuo Tiaozhi granule (HTG) comparison. No untreated-control RAW selected.